BioHarvest Sciences (NASDAQ:BHST) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) posted its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01, Zacks reports. BioHarvest Sciences had a negative return on equity of 1,041.86% and a negative net margin of 36.33%.The firm had revenue of $9.07 million during the quarter, compared to analyst estimates of $9.24 million.

Here are the key takeaways from BioHarvest Sciences’ conference call:

• Q4 revenue was $9.1M (+25% YoY) and full‑year revenue was $34.5M (+37% YoY), with Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%), and year‑end cash of $23M, reflecting materially stronger profitability and liquidity.
• The VINIA direct‑to‑consumer business exceeded 85,000 active users, earned the #1 U.S. resveratrol brand position, and the new VINIA Blood Flow Hydration launch is showing strong early traction (15% of new‑customer revenue and ~4.8–4.9 ratings), prompting a shift to digital marketing to reach younger cohorts.
• The CDMO unit hit a major technical milestone by completing stage one for a rare fragrance plant (first‑ever stable cell culture), retains 20% ownership of resulting compositions, has four active third‑party programs (including Tate & Lyle and Saffron Tech), and expects external CDMO revenue to rise toward $4–6M in 2026.
• Management is investing heavily in CDMO and manufacturing capabilities (AI, process engineering, elicitation center) and increasing marketing spend, which will make near‑term results lumpy and raise operating expenses but is presented as a deliberate trade‑off to accelerate growth in 2027–2028.

BioHarvest Sciences Trading Up 0.6%

Shares of BioHarvest Sciences stock traded up $0.03 on Wednesday, hitting $4.37. 5,384 shares of the company traded hands, compared to its average volume of 26,156. The company has a current ratio of 1.35, a quick ratio of 1.02 and a debt-to-equity ratio of 0.30. The company has a market cap of $85.64 million, a PE ratio of -6.42 and a beta of 1.14. The stock’s 50 day moving average price is $4.61 and its 200-day moving average price is $6.65. BioHarvest Sciences has a 52 week low of $4.10 and a 52 week high of $12.80.

Analyst Ratings Changes

Several research firms have recently issued reports on BHST. Roth Mkm began coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Institutional Trading of BioHarvest Sciences

A number of hedge funds have recently bought and sold shares of BHST. Alyeska Investment Group L.P. acquired a new stake in shares of BioHarvest Sciences in the 4th quarter worth $3,929,000. Evercore Wealth Management LLC purchased a new stake in BioHarvest Sciences in the fourth quarter valued at about $724,000. Osaic Holdings Inc. boosted its holdings in BioHarvest Sciences by 5,510.4% in the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock worth $183,000 after acquiring an additional 34,605 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of BioHarvest Sciences during the fourth quarter worth about $173,000. Finally, Jane Street Group LLC acquired a new position in shares of BioHarvest Sciences during the fourth quarter valued at about $145,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.